Jul 29
Quarterly report
10-Q
Ended Oct 31
Quarterly report for the period ended Oct 31, 2020
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Jul 29, 2022
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MAJI
this stock
Nextel Medical Corp.
|
$38,726 | -94.4% | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$137.57B | +19.7% | +46.2% | 34.9 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.40B | +23.2% | +20.8% | 21.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$93.61B | +684.5% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MAJI | +3.3% | +3.3% | -71.8% | -13.9% | -94.4% |
| SPY | +3.3% | -1.9% | +1.5% | +0.2% | +11.0% |
| vs SPY | +0.0% | +5.2% | -73.4% | -14.1% | -105.4% |